Literature DB >> 1483945

p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

T Nakamura1, I Yana, T Kobayashi, E Shin, K Karakawa, S Fujita, A Miya, T Mori, I Nishisho, S Takai.   

Abstract

Anaplastic carcinoma of the thyroid gland, which is one of the most aggressive, malignant tumors in humans, is considered to originate from preexisting differentiated thyroid cancer. To define the genetic alterations associated with such progression, we examined nine cases of anaplastic thyroid carcinoma for mutation in exons 4-9 of the p53 tumor suppressor gene. Preliminary screening for mutation by RNase protection analysis demonstrated that two out of nine anaplastic carcinomas contained sequence alterations in the p53 gene. Subsequent DNA sequencing identified the mutated nucleotides in these two cases; one was a nonsense mutation at codon 165, and the other was a single-base deletion at codon 176 resulting in the creation of a stop codon downstream due to frameshift. The fact that no mutations were detected in coexisting foci of papillary carcinomas from the same patients shows that these mutations of the p53 gene occurred after development of papillary carcinomas. These results suggest that p53 gene mutation triggers the progression from differentiated into anaplastic carcinoma in the human thyroid gland.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483945      PMCID: PMC5918745          DOI: 10.1111/j.1349-7006.1992.tb02761.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

1.  Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis.

Authors:  A Foti; H G Ahuja; S L Allen; P Koduru; M W Schuster; P Schulman; M Bar-Eli; M J Cline
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

2.  Structure and transforming potential of the human cot oncogene encoding a putative protein kinase.

Authors:  J Miyoshi; T Higashi; H Mukai; T Ohuchi; T Kakunaga
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

3.  Pathology of thyroid tumors: some recent and old questions.

Authors:  J Rosai; M L Carcangiu
Journal:  Hum Pathol       Date:  1984-11       Impact factor: 3.466

4.  Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.

Authors:  Y S Venkatesh; N G Ordonez; P N Schultz; R C Hickey; H Goepfert; N A Samaan
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis.

Authors:  B Jereb; J Stjernswärd; T Löwhagen
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860

7.  The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemids, phages or plasmids suitable for sequencing.

Authors:  G Del Sal; G Manfioletti; C Schneider
Journal:  Biotechniques       Date:  1989-05       Impact factor: 1.993

8.  High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

Authors:  D D'Amico; D Carbone; T Mitsudomi; M Nau; J Fedorko; E Russell; B Johnson; D Buchhagen; S Bodner; R Phelps
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

9.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

View more
  31 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

3.  Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors:  Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

4.  Clinicopathological findings and p53 expression of thyroid cancer in children.

Authors:  T Kobayashi; H Nakanishi; I Yana; I Nishisho; Y Itoh; E Wakasugi; T Takeda; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Anaplastic thyroid cancer and hyperthyroidism.

Authors:  Vijay Kumar; Bruno Blanchon; Xin Gu; Marjorie Fowler; David Scarborough; Cherie Ann Nathan; Subhashini Yaturu
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 6.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

7.  Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.

Authors:  Naoyoshi Onoda; Masanori Nakamura; Naoki Aomatsu; Satoru Noda; Shinichiro Kashiwagi; Kosei Hirakawa
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

8.  The likely transformation of papillary thyroid carcinoma into anaplastic carcinoma during postoperative radioactive iodine-131 therapy: report of a case.

Authors:  K Shingu; S Kobayashi; S Yokoyama; M Fujimori; K Asanuma; K I Ito; Y Hama; M Maruyama; R Kusama; J Amano
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

9.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

10.  Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.

Authors:  J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.